Introducing the first-generation DNA targeted BPUs that combine CRISPR technology with the ultra-sensitivity of graphene-based field effect transistors (gFETs) to detect target DNA sequences within the whole genome without the need for DNA amplification.
Early electronic calculation devices were “fixed-program computers,” wired up to perform a pre-defined mathematical process. It took decades to integrate the idea of the transistor, software, and create a computational platform and core of modern computer: the Central Processing Unit or CPU. Similarly, we have had several decades of electronic and electrochemical devices that integrate with biology to perform limited biological measurements that rely more on sample processing to drive performance than any aspect of the electronic nature of the measurement. For most biological measurements, using an optical readout has been more convenient and just as effective. That changes with the integration of complex biochemistry, nanoelectronics, data analysis software, scaled semiconductor manufacturing, and biology driven assay development into a device called a Biosignal Processing Unit or BPU.
Simultaneous with the development of the BPU, the discovery of CRISPR technology has revolutionized the fields of transcriptional activation and repression, genome editing, gene-based therapeutics, and diagnostics. The applications of this technology have been rapidly expanding as researchers continue to discover new Cas enzymes, engineer high fidelity Cas orthologs, and modify and synthesize guide RNAs to efficiently direct these Cas enzymes to their targets.
In this talk, we will introduce the first-generation DNA targeted BPUs that combine CRISPR technology with the ultra-sensitivity of graphene-based field effect transistors (gFETs) to detect target DNA sequences within the whole genome without the need for DNA amplification. This technology, termed CRISPR-Chip™, utilizes the genome searching capability of Cas and reprogrammable RNA molecule to unzip the double-stranded DNA and bind to its target. This binding event causes a change in graphene conductivity which can be detected in real-time within the gFET construct. CRISPR-Chip was utilized to detect target genes within clinical samples obtained from patients with Duchenne Muscular Dystrophy (Cover of Nature BME-2019), and single cell point mutations in Sickle cell disease and ALS without the need for amplification (Nature BME 2021), within less than 30 minutes. The applications of this technology platform go beyond diagnostics. CRISPR-Chip can provide greater insights on the mechanism of CRISPR and can lead to safe and more effective utilization of this gene editing technology for therapeutic applications.
This post was originally published at https://www.cardeabio.com/news/agbt-abstrat-2022. Cardea Bio was acquired by Paragraf on 2 May 2023.